Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
1/2期
提前终止
NCT04331067
| 适应症 | Triple Negative Breast Cancer |
|---|
| 分期 | 1/2期 |
|---|
| 申办方 | Washington University School of Medicine |
|---|
| 状态 | 提前终止 |
|---|
| 受试者人数 | 15 人 |
|---|
| 干预（药物） | Paclitaxel, Carboplatin, Nivolumab, Cabiralizumab, Tumor biopsy |
|---|
| 开始日期 | 2020年11月19日 |
|---|
| 完成日期 | 2023年3月20日 |
|---|
| 结果公布日 | 2024年5月16日 |
|---|
摘要
Prior to Amendment #7: The hypothesis of this study is that the combination of cabiralizumab and nivolumab with neoadjuvant chemotherapy will decrease tumor associated macrophages (TAMs) and increase tumor infiltrating lymphocytes (TIL) compared to neoadjuvant chemotherapy plus nivolumab in patients with early stage triple-negative breast cancer (TNBC) and improve clinical outcomes. As of Amendment #7 IRB approved 10/13/2022: The study will no longer enroll to Arm B. Cabiralizumab will no longer be given. The hypothesis of this study is that on-treatment tumor associated macrophages (TAMs) and tumor infiltrating lymphocytes (TILs) will improve (reduced TAMs, increased TILs) following neoadjuvant nivolumab with chemotherapy.
Percent Change in Tumor Infiltrating Lymphocytes (TILs)
Baseline and week 5 · percent change
| Arm A and Unrandomized Arm: Neoadjuvant Chemo + Nivolumab | 95.2 ± 121 percent change |
|---|
| Arm B: Neoadjuvant Chemo + Nivolumab + Cabiralizumab | 1.63 ± 82.5 percent change |
|---|
Percent Change in Tumor Associated Macrophages (TAMs)
Baseline and week 5 · percent change
| Arm A and Unrandomized Arm: Neoadjuvant Chemo + Nivolumab | 31.8 ± 32.1 percent change |
|---|
| Arm B: Neoadjuvant Chemo + Nivolumab + Cabiralizumab | -38.7 ± 63.6 percent change |
|---|
Safety of the Regimen as Measured by Incidence of Adverse Events (Safety lead-in Only)
From start of treatment through 100 days after last day of study treatment or surgery whichever occurs first (approximately 16 weeks) · Participants
| Arm A: Neoadjuvant Chemo + Nivolumab | 4 Participants |
|---|
| Arm B: Neoadjuvant Chemo + Nivolumab + Cabiralizumab | 2 Participants |
|---|
| Arm A: Neoadjuvant Chemo + Nivolumab | 2 Participants |
|---|
| Arm B: Neoadjuvant Chemo + Nivolumab + Cabiralizumab | 4 Participants |
|---|
| Arm A: Neoadjuvant Chemo + Nivolumab | 1 Participants |
|---|
| Arm B: Neoadjuvant Chemo + Nivolumab + Cabiralizumab | 0 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。